View the news highlights below to learn more about the TechEmerge program and current pilots!
CHENNAI, India, January 8, 2019 /PRNewswire/ --
MobileODT, developer of the Enhanced Visual Assessment (EVA) System, will partner with Genworks and Apollo Hospitals to deliver its FDA-cleared smart mobile colposcope in India to perform the first large-scale pilot of Augmented Intelligence (AI) for use in cervical cancer screening. This will give healthcare professionals cutting edge, yet low-cost mobile technology to reach millions of women across India who previously had limited access to life saving cervical exams.
New Delhi, To bring Intensive Care Unit (ICU)-standard monitoring across general wards, Max Healthcare on Wednesday announced a partnership with US-based medical technology company Vios Medical to launch a continuous vital monitoring system built on a medical-grade Internet of Things (IoT) framework.
Zilico Ltd continues its global expansion plans for ZedScan™ by securing a strategic deal with the MaxHealth Medicine Group (China), stock code: 836163 (NEEQ). The deal will allow MaxHealth to sell and market ZedScan™, Zilico’s cervical cancer diagnostic system, to the Chinese market.
WellDoc and Voluntis, two companies with FDA-cleared, clinically validated platforms aimed at the management of Type 2 diabetes, have signed a commercial agreement to combine their technologies and offer joint products in the future.
Stasis Labs found its first market overseas. What's its best next move?
An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month.